Iovance Biotherapeutics (IOVA) News Today $5.78 +0.17 (+3.03%) Closing price 04:00 PM EasternExtended Trading$5.79 +0.01 (+0.17%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six haveFebruary 21 at 2:25 AM | marketbeat.comIovance Biotherapeutics (IOVA) to Release Earnings on WednesdayIovance Biotherapeutics (NASDAQ:IOVA) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 3:54 AM | marketbeat.comIovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025February 18 at 4:01 PM | globenewswire.comRice Hall James & Associates LLC Reduces Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Rice Hall James & Associates LLC trimmed its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,594,532 shares of tFebruary 18 at 6:49 AM | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3% - Still a Buy?Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 7.3% - Still a Buy?February 15, 2025 | marketbeat.comBanque Pictet & Cie SA Acquires 54,832 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Banque Pictet & Cie SA raised its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 17.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 376,591 shares of the biotechnology company's sFebruary 15, 2025 | marketbeat.comIovance Biotherapeutics call volume above normal and directionally bullishFebruary 14, 2025 | markets.businessinsider.comStifel maintains Buy on Iovance Biotherapeutics, target at $21February 12, 2025 | msn.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)February 12, 2025 | globenewswire.comIovance Biotherapeutics Appoints Dan Kirby as Chief Commercial OfficerSAN CARLOS, Calif., February 10, 2025 – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leader in commercial biotechnology focused on innovating, developing, and delivering novel pFebruary 12, 2025 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month Low - What's Next?Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 1-Year Low - Here's What HappenedFebruary 10, 2025 | marketbeat.comIovance Biotherapeutics, Inc.: Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial OfficerFebruary 10, 2025 | finanznachrichten.deIovance Biotherapeutics appoints new chief commercial officerFebruary 10, 2025 | msn.comIovance Biotherapeutics appoints Kirby as Chief Commercial OfficerFebruary 10, 2025 | markets.businessinsider.comIovance Biotherapeutics Appoints Dan Kirby as Chief Commercial OfficerFebruary 10, 2025 | globenewswire.comJennison Associates LLC Purchases New Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Jennison Associates LLC purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 66,568 shares of the biotechnology company's stock,February 8, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst DowngradeIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month Low After Analyst DowngradeFebruary 4, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low Following Analyst DowngradeIovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year Low After Analyst DowngradeFebruary 3, 2025 | marketbeat.com69,625 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by SG Americas Securities LLCSG Americas Securities LLC acquired a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 69,625 shares of the biotechnology company's stFebruary 2, 2025 | marketbeat.comPiper Sandler Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)January 31, 2025 | markets.businessinsider.comIovance Biotherapeutics price target lowered to $7.50 from $10 at Piper SandlerJanuary 31, 2025 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $7.50 at Piper SandlerPiper Sandler decreased their price objective on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a "neutral" rating on the stock in a research report on Friday.January 31, 2025 | marketbeat.comTruist Financial Releases a Buy Rating on Iovance Biotherapeutics (IOVA)January 30, 2025 | markets.businessinsider.comTruist maintains Buy on IOVA stock with a $25 targetJanuary 30, 2025 | msn.comWhat's Wrong With Iovance Biotherapeutics Stock?January 30, 2025 | fool.comAnalysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have given a buy raJanuary 30, 2025 | marketbeat.comWhere Will Iovance Biotherapeutics Be in 5 Years?January 29, 2025 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA) and Madrigal Pharmaceuticals (MDGL)January 27, 2025 | markets.businessinsider.comStifel maintains Buy on Iovance stock with $21 targetJanuary 27, 2025 | msn.comMeet the Growth Stock That Could Soar 280%, According to Wall Street AnalystsJanuary 27, 2025 | fool.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy ratJanuary 27, 2025 | marketbeat.comInsider Stock Buying Reaches US$48.3m On Iovance BiotherapeuticsJanuary 24, 2025 | finance.yahoo.comPeninsula biotech company sues insurance company to cover patients' injuries in clinical trialsJanuary 24, 2025 | bizjournals.comIovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low - What's Next?Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year Low - What's Next?January 23, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low - Here's WhyIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low - Should You Sell?January 21, 2025 | marketbeat.comIs Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 21, 2025 | msn.comAssenagon Asset Management S.A. Takes Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Assenagon Asset Management S.A. bought a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,746,877 shares of the biotechnology company'January 19, 2025 | marketbeat.com3 Stocks That Could Turn $1,000 Into $5,000 by 2030January 18, 2025 | fool.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)January 17, 2025 | globenewswire.comIOVA Stock Touches 52-Week Low at $5.76 Amid Market ChallengesJanuary 16, 2025 | msn.comWells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)January 16, 2025 | markets.businessinsider.comWells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)January 16, 2025 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low - Should You Sell?Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low - What's Next?January 16, 2025 | marketbeat.comCancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff OverblownJanuary 10, 2025 | msn.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8% - Time to Sell?Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.8% - Here's WhyJanuary 10, 2025 | marketbeat.comIovance Biotherapeutics Shares Are Falling Today: What's Going On?January 10, 2025 | benzinga.com3 Mid-Cap Stocks That Could Take Off in 2025January 9, 2025 | fool.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - What's Next?Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low - Here's WhyJanuary 8, 2025 | marketbeat.comWhy Iovance Biotherapeutics Stock Zoomed More Than 5% Higher TodayJanuary 2, 2025 | fool.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7% - Here's What HappenedIovance Biotherapeutics (NASDAQ:IOVA) Trading Up 7.7% - Still a Buy?January 2, 2025 | marketbeat.com Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Media Mentions By Week IOVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.650.60▲Average Medical News Sentiment IOVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼77▲IOVA Articles Average Week Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Legend Biotech News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Blueprint Medicines News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Elanco Animal Health News Today Lantheus News Today Nuvalent News Today Cytokinetics News Today Verona Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
